HD Clinical Trials

SIGNAL Clinical Trial for Huntington’s Disease

Another Sponsor at the Huntington’s Disease Society of America in Boston last June was Vaccinex, Inc

Vaccinex and the Huntington Study Group (HSG) launched a trial for people with the gene mutation that causes HD who are either early in the progression of the disease or are not yet diagnosed with the disease.

SIGNAL, a Phase 2, multi-center, randomized, double-blind, placebo controlled study in subjects with early manifest and late prodromal Huntington’s disease (HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503 (pepinemab). Pepinemab a monoclonal antibody that is a potential treatment for Huntington’s disease (HD).  What-is-hd/overview-of-huntingtons-disease/

On January 16, 2019, Vaccinex, Inc. announced the enrollment was complete and includes two cohorts with a total of 265 Huntington’s Disease subjects – 179 in group 1 (B1) who have early manifest disease and 86 in group 2 (B2) who are late prodromal.  All subjects are randomized to receive monthly infusions of either VX15/2503 (pepinemab) or placebo for 18 months in double-blind fashion without crossover.

To read more about the SIGNAL trial, visit http://ir.vaccinex.com/news-releases/news-release-details/vaccinex-inc-announces-completion-enrollment-its-signal

To read FAQ regarding about the trial visit: https://huntingtonstudygroup.org/signal-faq/

Please visit my Author Website to read my blogs about Huntington’s disease and my personal experience  https://www.theresecrutchermarin.com

We Can Never Lose HOPE……………….

Author Therese Crutcher-Marin

Previous Post Next Post

You Might Also Like

No Comments

Leave a Reply

%d bloggers like this: